Correction of intestinal microbiocenosis as a preventive measure for progression of chronic kidney disease
https://doi.org/10.21518/2079-701X-2018-14-84-89
Abstract
At present, much attention is paid to the study of the influence of gut microbiota on the development of many diseases of internal organs, including chronic kidney disease. Thus, changes of gut microbiota in the qualitative and quantitative composition toward increasing the proteolytic flora, which is the source of the formation of uremic toxins, endotoxinemia, systemic inflammation, secondary immunodeficiency and cardiovascular complications, contribute to the worsening of the course and the progression of chronic kidney disease. That why the use of medicines which normalize gut microbiota, is the significant aspect of preventing the progression of chronic kidney disease.
About the Authors
M. S. Barilko
Sokolov Clinical Hospital No 122 of the Federal Bio-Medical Agency
Russian Federation
Russian Federation
P. V. Seliverstov
Mechnikov North-Western State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
V. G. Radchenko
Mechnikov North-Western State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
A. A. Murzina
Mechnikov North-Western State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Bello AK, Levin A, Tonelli M et al. Assessment of Global Kidney Health Care Status. JAMA, 2017, 317(18): 1864-1881.
2. Tomilina NA, Andrusev AM, Peregudova NG, Shinkareva MB. Substitution therapy of terminal chronic renal failure in the Russian Federation in 2010-2015. Report on the data of the All-Russian Register of Renal Substitution Therapy of the Russian Dialysis Society. Part one. Nefrologiya i Dializ, 2017, 4 (19): 1-95.
3. Smirnov AV, Shilov EM, Dobronravov VA, Kayukov IG, Bobkova IN, Shvetsov MYu, Tsygin AN, Shutov AM. Chronic kidney disease: the basic principles of screening, diagnosis, prevention, and approaches to treatment. National guidelines. SPb.: Levsha Publishing House, 2012. 51 p.
4. Wong J, Piceno YM, De Santis TZ et al. Expansion of urease and uricase-containing, indole- and p-cresol-forming and contraction of short chain fatty acid-producing intestinal bacteria in ESRD. Am J Nephrol, 2014, 39: 230-237.
5. McIntype CW, Harrison LE, Eldehni MT et al. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol, 2011, 6(1): 133-141.
6. Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int, 2013, 83: 1010-16.
7. Evenepoel P, Poesen R. The gut-kidney axis. Pediatr Nephrol, 2016, 32(11): 2005-2014.
8. Meijers BKI, Evenepoel P. The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant, 2011, 26: 759-761.
9. Pan W, Kang Y. Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies. Int Urol Nephrol, 2017: 1-11.
10. Sabatino A. et al. Alterations of intestinal barrier and microbiota in chronic kidney disease. Nephrol Dial Transplant, 2015, 30: 924-933. 11. Khodor SA, Shatat IF. Gut microbiome and kidney disease: a bidirectional relationship. Pediatr Nrphrol, 2017, 32: 921-931.
11. Aitbaev KA, Murkamilov IT, Kaliev RR. Chronic kidney disease: the pathophysiological role of intestinal dysbiosis and the renoprotective effectiveness of interventions for its modulation. RMJ, 2016, 22 (3): 157-162.
12. Actual issues of correction of intestinal microbiocenosis. A study guide. Under the editorship of Radchenko VG, Dobritsa VP, Seliverstova PV, Teterina LA, Chikhacheva EA. St. Petersburg, 2012. 20 pp.
13. Ramezani A, Massy ZA, Meijers B, Evenepoel P, Vanholder R. Role of the gut microbiome in uremia: a potential therapeutic target. Am J Kidney Dis, 2016, 67(3): 483-498.
14. Barilko MS, Seliverstov PV, Radchenko VG. The role of intestinal microflora in the development of chronic kidney disease. Vrach, 2017, 1: 5-11.
15. Barilko MS, Seliverstov PV, Radchenko VG. Modern enterosorption in patients with chronic kidney disease at the pre-dialysis stage. Pharmateся, 2016, 6: 76-83.
16. Ardatskaya MD, Belmer SV, Dobritsa VP, Zakharenko SM, Lazebnik LB, Minushkin ON, et al. Dysbiosis (dysbacteriosis) of the intestine: the current state of the problem, complex diagnosis and therapeutic correction. Eksperimentalnaya i Klinicheskaya Gastroenterologiya, 2015, 117 (5): 13-50.
17. The Human Microbiome Project consortium. Structure, function and diversity of the healthy microbiome. Nature, 2012, 486(7402): 207-214.
18. Vaziri ND. CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypert, 2012, 21: 587-592.
19. Preparations for correcting dysbiosis: functional nutrition. Ed. by Suvorov AN. SPb., 2015. 15 p.
20. Radchenko VG, Seliverstov PV, Zagorodnikova KA, Polyakova VV, Alekhina GG, Barilko MS. Pat. 2646467 RF IPC A61K 35/66, A61P 13/12. The method of treatment of patients with chronic kidney disease C3-C5 at the pre-dialysis stage, excluding pyelonephritis, urolithiasis. No. 2017113189. Stated 04/17/2017. Published. 03/5/2018. Bul. No. 7. 18 p.
Review
For citations:
Barilko MS, Seliverstov PV, Radchenko VG, Murzina AA. Correction of intestinal microbiocenosis as a preventive measure for progression of chronic kidney disease. Meditsinskiy sovet = Medical Council. 2018;(14):84-89. (In Russ.) https://doi.org/10.21518/2079-701X-2018-14-84-89
Views:
659
Email this article 